Jefferies rates Hana Biosciences at buy

Hana Biosciences Inc. was rated at buy by Jefferies & Co., Inc. analyst Adam Walsh on results from the analyst's proprietary survey of 22 U.S. oncologists. which suggest robust uptake for Zensana, if approved. Shares of the South San Francisco, Calif.-based biopharmaceutical company were up 5 cents, or 0.57%, at $8.80 on volume of 95,129 shares versus the three-month running average of 191,418 shares. (Nasdaq: HNAB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.